Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exploring Pleiotropic Effects of Lipid Modifiers and Targets on Measures of the Coagulation System with Genetics

1 Dec 2021

Abstract excerpt

Abstract Background Statins have long been suspected to have pleiotropic effects via thrombotic factors. Randomized controlled trials are too limited to be definitive. We examined the associations of genetically mimicking effects of statins, PCSK9 inhibitors, and alternative lipid targets (in genes LDLR, APOC3, and LPL) on key indicators of coagulation system function, i.e., prothrombin time (PT) and activated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiplatelet Therapy and Cardiovascular Diseases
Share to Genetic Associations and Epidemiology
Share to Lipoproteins and Cardiovascular Health

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34852378
DOI: 10.1055/a-1711-0946

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exploring Pleiotropic Effects of Lipid Modifiers and Targets on Measures of the Coagulation System with GeneticsPMID 34852378Read ↗

Investigating pleiotropic effects of statins on ischemic heart disease in the UK Biobank using Mendelian randomisationSemantic proximity Read ↗

Pleiotropic effects of statins on ischemic heart disease: a Mendelian Randomization study in the UK BiobankSemantic proximity Read ↗

Association of genetic variants related to combined lipid-lowering and antihypertensive therapies with risk of cardiovascular disease: 2 × 2 factorial Mendelian randomization analyses.Semantic proximity Read ↗

Factorial Mendelian randomization of lipoprotein (a) lowering, low-density lipoprotein cholesterol lowering, and lifestyle improvements: joint associations with cardiovascular risk.Semantic proximity Read ↗

Causal effects of lipid-lowering therapies on aging-related outcomes and risk of cancers: a drug-target Mendelian randomization study.Semantic proximity Read ↗

Coagulation Factors and the Risk of Ischemic Heart Disease: A Mendelian Randomization Study.Semantic proximity Read ↗

Pharmacogenomics, lipid disorders, and treatment options.Semantic proximity Read ↗

Genetically Proxied Inhibition of Coagulation Factors and Risk of Cardiovascular Disease: A Mendelian Randomization Study.Semantic proximity Read ↗

Drug Target Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Atrial Fibrillation.Semantic proximity Read ↗

Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for DyslipidemiaSemantic proximity Read ↗

Associations Between Gene Variants of Lipid-Lowering Drug Targets and Adverse Outcomes After Ischemic Stroke.Semantic proximity Read ↗

Gene-statin interaction study identifies 9 loci that moderate statin effectiveness in blood lipidsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.